Ferring Pharmaceuticals Announces Grand Opening of US Operations Center
Ferring Pharmaceuticals has expanded its footprint in New Jersey with the opening of its new US Operations Center on a 25-acre lot located at 100 Interpace Parkway in Parsippany. Instead of relocating its outsourcing manufacturing to other states or overseas, Ferring’s new center is a sign of the company’s continued commitment to New Jersey and bringing new jobs to the local community.
The facility recently completed the integration of staff into the state-of-the-art manufacturing suite and product development laboratories. The US Operations Center will house 275 employees across management, administration, commercial operations, manufacturing and R&D, a set up designed to allow unique opportunities for collaboration across various operational disciplines. Ferring plans to expand that number significantly as the manufacturing facility gradually comes online over the course of the next 18–24 months.
“This is just the start of an exciting journey of growth to come,” said Michel Pettigrew, CEO, Ferring Holding Inc. and President of the Executive Board and Chief Operating Officer, Ferring Group. “We hope this new operations center stands as a symbol of our philosophy as a company — a place where our commitment to the science and to our patients is front and center; a learning environment where employees are encouraged to take initiative and stretch beyond their designated role; and a cornerstone of the community, dedicated to giving back.”
The facility allows the company to reinforce its commitment to New Jersey at a time when many pharmaceutical companies are making out-of-state moves. The approach is an example of Ferring’s dedication to the community it serves. Moreover, the move to stay in state provides access to experienced pharmaceutical talent and world class academic institutions. Notably, Ferring is also working with several organizations in New Jersey to offer open positions to veterans of the US armed forces.
“This grand opening serves as a reminder of our commitment to the US, New Jersey and to our long-term view on the science that can make a real difference in the lives of the patients we serve,” said Aaron Graff, President and COO Ferring Pharmaceuticals Inc. “As I watch our teams start to integrate into the new operations center, I already see the positive impact the space has on our ability to collaborate across functions within the organization and provide a premium workspace for our employees.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance